Greenleaf Trust Makes New Investment in Liquidia Co. (NASDAQ:LQDA)

Greenleaf Trust bought a new stake in shares of Liquidia Co. (NASDAQ:LQDA) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 13,623 shares of the company’s stock, valued at approximately $164,000.

Several other institutional investors and hedge funds also recently made changes to their positions in LQDA. Fortitude Family Office LLC acquired a new stake in Liquidia in the fourth quarter worth $26,000. Aigen Investment Management LP acquired a new position in shares of Liquidia in the 3rd quarter valued at $80,000. SG Americas Securities LLC purchased a new stake in Liquidia in the 3rd quarter worth about $84,000. Cerity Partners LLC purchased a new stake in Liquidia in the 4th quarter worth about $197,000. Finally, Simplicity Solutions LLC purchased a new stake in Liquidia in the 3rd quarter worth about $136,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Stock Down 1.4 %

Shares of LQDA stock opened at $12.37 on Friday. The stock’s fifty day simple moving average is $14.55 and its 200 day simple moving average is $11.19. Liquidia Co. has a one year low of $5.71 and a one year high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The company had revenue of $4.53 million for the quarter, compared to analyst estimates of $5.29 million. Equities research analysts expect that Liquidia Co. will post -1.01 EPS for the current fiscal year.

Analysts Set New Price Targets

LQDA has been the subject of a number of recent research reports. HC Wainwright raised their price target on Liquidia from $16.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of Liquidia in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

Insider Buying and Selling

In other Liquidia news, General Counsel Russell Schundler sold 2,060 shares of the stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the sale, the general counsel now directly owns 486,027 shares in the company, valued at $7,086,273.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Liquidia news, General Counsel Russell Schundler sold 2,060 shares of the stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the sale, the general counsel now directly owns 486,027 shares in the company, valued at $7,086,273.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Roger Jeffs sold 8,360 shares of the stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $121,888.80. Following the transaction, the chief executive officer now owns 826,985 shares of the company’s stock, valued at $12,057,441.30. The disclosure for this sale can be found here. Insiders sold a total of 70,999 shares of company stock valued at $1,100,444 over the last three months. Company insiders own 31.60% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).